Funding for this research was provided by:
Allegheny Health Network (Hopkins-Allegheny Cancer Research Fund)
Conquer Cancer Foundation (ASCO YIA)
American Association for Cancer Research (Incyte Immuno-Oncology Research Fellowship)
National Cancer Institute (T32CA00971-38, R50CA243627)
Emerson Cancer Research Fund
The Johns Hopkins Cancer Convergence Institute
Received: 31 May 2020
Accepted: 23 April 2021
First Online: 13 May 2021
: The human datasets generated during this study did not involve obtaining tissue or information from living individuals. All postmortem samples were collected under approved individualized consent, IRB protocol NA_00036610 as well as the Johns Hopkins hospital autopsy consent (the latter signed by the legal next of kin). Animal experiments and euthanasia were performed in accordance with Johns Hopkins IACUC–approved protocols.
: WH reports co-inventorship of patents with potential for receiving royalties from Rodeo Therapeutics, receiving research grant from Sanofi, and consulting for Exelixis. MY reports receiving a commercial research grant from Bristol-Myers Squibb, Exelixis, and Merck & Co and is a consultant/advisory board member for Eisai and Exelixis. EJF is a consultant for Champions Oncology. EMJ reports receiving a commercial research grant from Bristol-Myers Squibb, Aduro Biotech, and Amgen; has ownership interest (including stock, patents, etc.) in Aduro Biotech; and is a consultant/advisory board member for CStone, Dragonfly, Genocea, and Adaptive Biotechnologies.